HeyJaredAndrea S. Blevins Primeau
- Indexed articles, last 90 days
- 12
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Cancer Therapy Advisor
- Top 5M sites
- Earliest in this view
- Jul 17, 2026
Latest articles
Promising Results With Anti-BCMA/GPRC5D CAR-T in RRMM With Extraosseous EMD - Oncology Nurse Advisor (opens the original)
Read excerpt
Treatment of patients with relapsed/refractory multiple myeloma (RRMM) with extraosseous extramedullary disease (EMD) with an anti-BCMA/GPRC5D chimeric antigen receptor (CAR) T-cell therapy resulted in promising results with high response rates, according to data from a phase 2 trial published in Blood. In this open-label, phase 2 trial (ClinicalTrials.gov Identifier: NCT05509530), 37 patients with RRMM and extraosseous EMD were treated with anti-BCMA/GPRF5D CAR-T therapy. The primary endpoint w
Promising Results With Anti-BCMA/GPRC5D CAR-T in RRMM With Extraosseous EMD (opens the original)
Read excerpt
Treatment of patients with relapsed/refractory multiple myeloma (RRMM) with extraosseous extramedullary disease (EMD) with an anti-BCMA/GPRC5D chimeric antigen receptor (CAR) T-cell therapy resulted in promising results with high response rates, according to data from a phase 2 trial published in Blood. In this open-label, phase 2 trial (ClinicalTrials.gov Identifier: NCT05509530), 37 patients with RRMM and extraosseous EMD were treated with anti-BCMA/GPRF5D CAR-T therapy. The primary endpoint w
6/8 HLA-Mismatched Unrelated Donors Transplantation Outcomes “Encouraging” - Oncology Nurse Advisor (opens the original)
Read excerpt
The 1-year outcomes of peripheral blood stem cell (PBSC) transplantation using 6/8 HLA-mismatched unrelated donors (MMUD) were considered encouraging, according to a report published in Blood Advances. However, the researchers noted, “Because donor match level was not prospectively assigned and between-group comparisons were exploratory, these findings are descriptive and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.” In the multicenter, phase 2 ACCESS tria
6/8 HLA-Mismatched Unrelated Donors Transplantation Outcomes “Encouraging” (opens the original)
Read excerpt
The 1-year outcomes of peripheral blood stem cell (PBSC) transplantation using 6/8 HLA-mismatched unrelated donors (MMUD) were considered encouraging, according to a report published in Blood Advances. However, the researchers noted, “Because donor match level was not prospectively assigned and between-group comparisons were exploratory, these findings are descriptive and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.” In the multicenter, phase 2 ACCESS tria
Consensus Recommendations Published for CAR-T Therapy in Adult ALL (opens the original)
Read excerpt
Consensus recommendations about the use of chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL), including patient selection, bridging treatment, lymphodepletion, treatment setting, response assessment, maintenance therapy, and toxicity prevention and management were published in the journal Blood. The expert panel, which consisted of principal investigators from Real World Outcomes Collaborative of CAR T-Cell Therapy in Adult ALL (ROCCA) conso
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
Top 5M sites
For Cancer Therapy Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.